Invention Grant
US09439986B2 Tricarbonyl technetium-99m, rhenium-185/187, or rhenium-188 labeled cyclic RGD derivatives and uses thereof
有权
三羰基锝-99m，铼-185 / 187或铼-188标记的环状RGD衍生物及其用途
- Patent Title: Tricarbonyl technetium-99m, rhenium-185/187, or rhenium-188 labeled cyclic RGD derivatives and uses thereof
- Patent Title (中): 三羰基锝-99m，铼-185 / 187或铼-188标记的环状RGD衍生物及其用途
-
Application No.: US13699511Application Date: 2011-05-24
-
Publication No.: US09439986B2Publication Date: 2016-09-13
- Inventor: Byung Chul Lee , Sang Eun Kim , Ji Sun Kim , Byung Seok Moon , Jae Ho Jung
- Applicant: Byung Chul Lee , Sang Eun Kim , Ji Sun Kim , Byung Seok Moon , Jae Ho Jung
- Applicant Address: KR Seoul
- Assignee: BIO IMAGING KOREA CO., LTD.
- Current Assignee: BIO IMAGING KOREA CO., LTD.
- Current Assignee Address: KR Seoul
- Agency: Lucas & Mercanti, LLP
- Priority: KR10-2010-0048289 20100524; KR10-2011-0043544 20110509
- International Application: PCT/KR2011/003801 WO 20110524
- International Announcement: WO2011/149250 WO 20111201
- Main IPC: A61K51/00
- IPC: A61K51/00 ; A61M36/14 ; A61K51/08 ; C07K7/64 ; G01N33/574 ; G01N33/60
Abstract:
The present invention relates to tricarbonyl technetium-99m or rhenium-188 labeled cyclic RGD derivatives, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment (radiotherapy) of angiogenesis-related diseases. The tricarbonyl technetium-99m or rhenium-188 labeled cyclic RGD derivatives of the present invention has a high subnanomolar affinity to integrin αvβ3 (also called as a vitronectin receptor) that is activated in an angiogenic action induced by a tumor, and acts exclusively upon cancer cells having selectively activated integrin αvβ3 because of a substantially low intake into the liver and intestines.
Public/Granted literature
Information query
